Μπορείτε να στέλνετε ειδήσεις και Δελτία Τύπου στο email μας.
Αν θέλετε να επικοινωνήσετε μαζί μας ή να στείλετε Δελτίο Τύπου πατήστε εδώ...pharmamarketingexpertsblog@gmail.com


Τρίτη 19 Ιουνίου 2012

Lundbeck plans to establish a more flexible commercial organisation in Europe


H. Lundbeck A/S (Lundbeck) today announced plans to restructure its commercial organisation in Europe. The aim is partly to establish a more flexible commercial infrastructure with respect to detailing to general practitioners ahead of multiple future product launches and partly to maintain cost control. The plan is to uphold Lundbeck's position as a leading CNS specialist and secure successful launches of new products. 

The proposed restructuring is intended to pave the way for a successful transition of Lundbeck's European product portfolio with several potential product launches in the coming years. Furthermore, the initiative aims to mitigate increased pressure from healthcare reforms, generic competition and uncertainty regarding pricing and reimbursement in Europe.


"The market environment in Europe is changing rapidly at a time when Lundbeck has numerous new products to launch. To ensure a successful transition of our product portfolio in Europe we need a more flexible commercial infrastructure and to maintain cost control," says Ulf Wiinberg, President and CEO of Lundbeck. 

Lundbeck continues to invest in growth markets

This project is expected to involve the reduction of around 600 positions in our subsidiaries primarily in Europe. Lundbeck will continue with the current plans for investments in markets of growth comprising the US and International Markets. 

Lundbeck cares for employees who may be laid off. We will do our utmost to manage the process in a respectful way and will now initiate a consultation process regarding the anticipated staff reductions with the works councils in the most affected markets. Lundbeck has informed the company's European Works Council about the restructuring plans.